Le Lézard
Classified in: Health
Subjects: RCL, PSF

Food Recall Warning - Certain Abbott brand powdered infant formula products recalled due to possible Cronobacter sakazakii and Salmonella


OTTAWA, ON, June 19, 2022 /CNW/ -

Summary
Affected products

Brand

Product

Size

UPC

Codes

Abbott

Similac Advance Step 1 Milk-Based Iron-Fortified Infant Formula Powder

964 g

0 55325 00163 8

L28174SH0

L36099SH0

Abbott

Similac Advance Step 2 Milk-Based Iron-Fortified and Calcium-Enriched Infant Formula Powder

964 g

0 55325 00164 5

L31496SH0

L32642SH0

L29186SH0

Abbott

Similac Alimentum Step 1 Hypoallergenic Infant Formula Powder

400 g

0 55325 00061 7

L35026Z26

Abbott

Similac Advance Step 2 Milk-Based Iron-Fortified and Calcium-Enriched Infant Formula Powder

658 g

0 55325 00077 8

L27887SH0

L31497SH0

Issue

Shoppers Drug Mart is recalling certain Abbott brand powdered infant formula products from the marketplace due to possible Cronobacter sakazakii and Salmonella contamination. The products were previously recalled on February 17, 2022 and some units were sold via on-line in error.

What you should do

Food contaminated with Cronobacter sakazakii may not look or smell spoiled but can still make you sick. Although Cronobacter sakazakii is not commonly linked to human illness, in rare cases it can cause serious or fatal infections. Cronobacter sakazakii can cause rare bloodstream and central nervous system infections and has been associated with severe intestinal infection (necrotizing enterocolitis) and blood poisoning (sepsis), especially in newborns.

Food contaminated with Salmonella may not look or smell spoiled but can still make you sick. Young children, pregnant women, the elderly and people with weakened immune systems may contract serious and sometimes deadly infections. Healthy people may experience short-term symptoms such as fever, headache, vomiting, nausea, abdominal cramps and diarrhea. Long-term complications may include severe arthritis.

Learn more:

Background

This recall was triggered a consumer complaint.

There have been reported illnesses in the United States associated with the consumption of these products. However, there have been no reported illnesses in Canada associated with the consumption of these products.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.

The CFIA is verifying that industry is removing the recalled products from the marketplace.

Public enquiries and media

Company information  
Shoppers Drug Mart 
Telephone: 1-866-220-3837 

Public enquiries
Toll-free: 1-800-442-2342 (Canada and U.S.)
Telephone: 1-613-773-2342 (local or international)
Email: [email protected]

Media relations
Telephone: 613-773-6600
Email: [email protected]

                                                             Également disponible en français

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: